Market Overview

UPDATE: Topeka Capital Raises PT on Monsanto Company on Cross-Licensing Deal

Share:
Related MON
How Digital Farming Could Hurt Bayer, Monsanto
Lachapelle: If Bayer Expands In Animal Healthcare, Zoetis Is Obvious Choice
The Vetr community has upgraded $MON to 3-Stars. (Vetr)

In a report published Wednesday, Topeka Capital Markets analyst Chris Kapsch reiterated a Buy rating on Monsanto Company (NYSE: MON), and raised the price target from $113.50 to $120.50.

In the report, Kapsch noted, “The cross-licensing deal announced between DuPont and Monsanto is a meaningful positive for MON, increasing the likelihood that domestic soy farmers inevitably and ubiquitously adopt MON's next gen Roundup Ready to Yield (RR2Y) technology for soybeans. The deal also adds incremental earnings (via royalties, starting FY14) that may not have come through had DuPont endeavored to compete exclusively using first generation Roundup Ready (RR) trait technology, which comes off patent next year. Further, with DuPont embracing RR2Y, there is diminished risk the RR soy market comes under generic-based pricing pressure. We are increasing our FY14 EPS estimate to reflect the incremental royalties and our target price to reflect diminished risks that may have otherwise dragged on MON's multiple. We continue to use any volatility into/through March 28th (when the USDA crop planting intentions report is released) as an opportunity to buy MON.”

Monsanto Company closed on Tuesday at $103.79.

Latest Ratings for MON

DateFirmActionFromTo
Apr 2016Goldman SachsMaintainsSell
Apr 2016JP MorganMaintainsNeutral
Apr 2016CitigroupMaintainsNeutral

View More Analyst Ratings for MON
View the Latest Analyst Ratings

Posted-In: Topeka Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (MON)

View Comments and Join the Discussion!